Elite Provides Update on SequestOx™ New Drug Application

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Elite Provides Update on SequestOx™ New Drug Application

NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP ) today announced the Company met with the U.S. Food and Drug Administration (the “FDA”) on December 21, 2016 for an end-of-review meeting to discuss steps that Elite can take to obtain approval of SequestOx™.   Based on the FDA response, the Company believes there is a clear path forward to address the issues cited in the July 14 th Complete Response Letter (“CRL”). The FDA will provide minutes of the meeting by the end of January and the Company will issue a further update at that time.

SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride) is Elite’s investigational abuse-deterrent opioid candidate for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. The proposed plan submitted by the Company addresses items cited in the CRL dated July 14, 2016 for the New Drug Application (the “NDA”) for SequestOx™.

“We are extremely pleased that there is a path forward to seek FDA approval of SequestOx™,” said Nasrat Hakim, President and CEO of Elite. “Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately.”

About Elite Pharmaceuticals, Inc. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products.  Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.  Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International.  Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and the NDA for SequestOx™, for which it just received the CRL from the FDA.  Elite’s lead pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid.  These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse.  Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com .

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, the steps Elite may take as a result of the CRL, the results of an end-of-review meeting and what actions the FDA may require of Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without limitation, Elite’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Elite’s ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations 518-398-6222 Dianne@elitepharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 61

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 106

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 61

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 104

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 182

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 66

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 173

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 125

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 140

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading

Top 5 Most Recently Viewed Articles

Ford Motor Company Faces Legal Challenges: Key Insights

Updated Category News Views 119

Understanding the Legal Landscape for Ford Motor Company As investors navigate the intricate world of stock ownership, recent events surrounding Ford Motor Company have raised eyebrows. The company currently finds itself at the center of a class action lawsuit involving shareholders who acquired stock during a specific period. Class Action Overview and Important Dates...

Continue Reading
Transforming the Specialty Fats and Oils Industry for Success

Updated Category News Views 188

A Deep Dive into the Specialty Fats and Oils Market The landscape of the specialty fats and oils market is rapidly transforming, growing from its valuation of US$ 16.12 billion in the preceding year to a staggering US$ 31.69 billion by 2033, marking a robust CAGR of 7.8% during the next financial stretch. This growth signals a significant shift in industry dynamics and...

Continue Reading
C3.ai: Analyzing Current Trends in the Options Market

Updated Category News Views 241

Current Sentiment on C3.ai Recently, well-known investors—often referred to as whales—have taken a decidedly negative stance towards C3.ai. This growing skepticism stems from the history of options involving the company's stock. An analysis of C3.ai's (AI) trading patterns uncovered nine notable trades. Digging deeper into these transactions shows that only 22% of...

Continue Reading
CytomX Therapeutics Completes $100 Million Stock Offering

Updated Category News Views 315

CytomX Therapeutics Completes $100 Million Stock Offering CytomX Therapeutics, Inc. (NASDAQ: CTMX), based in South San Francisco, has just announced the pricing of an extensive stock offering. The company is set to offer 76,923,076 shares of its common stock at a price of $1.30 per share. This significant transaction aims to raise approximately $100 million and is being...

Continue Reading
Wall Street's Bullish Coverage Initiation Highlights for NKE and Others

Updated Category News Views 120

Wall Street Analysts Initiate Coverage on Key Stocks In a dynamic market landscape, top analysts have recently adjusted their ratings on several prominent companies. Their insights provide a glimpse into potential future performance for investors. Today, we spotlight these analyst ratings and what they mean for some notable stocks. NIKE, Inc. (NKE) Coverage by Needham...

Continue Reading